TY  - GEN
AU  - Cattrini, Carlo
AU  - Caffo, Orazio
AU  - De Giorgi, Ugo
AU  - Mennitto, Alessia
AU  - Gennari, Alessandra
AU  - Olmos, David
AU  - Castro, Elena
PY  - 2022
DO  - 10.3390/cancers14071792
SN  - 2072-6694
UR  - http://hdl.handle.net/20.500.12105/18799
AB  - Nonmetastatic castration-resistant prostate cancer (nmCRPC) represents a condition in which patients with prostate cancer show biochemical progression during treatment with androgen-deprivation therapy (ADT) without signs of radiographic progression...
LA  - eng
KW  - PSMA-PET
KW  - androgen-receptor signaling inhibitors
KW  - apalutamide
KW  - conventional imaging
KW  - darolutamide
KW  - enzalutamide
KW  - nmCRPC
KW  - nonmetastatic castration-resistant prostate cancer
TI  - Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review.
TY  - research article
ER  -